Clinical trials: Obese Adults
Prediabetes, Insulin Resistance
MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity
This Phase 2a study evaluates whether 12 weeks of treatment with investigational MOTS-c improves insulin sensitivity compared with placebo in adults with prediabetes and overweight/obesity.
- Conditions
- Prediabetes, Insulin Resistance, Overweight/Obesity
- Trial name
- MOTS-MET (NCT07505745)
- Testing
- MOTS-c (MDP), Route Subcutaneous injection, Regimen
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Hudson Biotech
Diabetes
A Study of CT-388 in Otherwise Healthy Overweight and Obese Adults and Patients With Type 2 Diabetes Mellitus
This is a first-in-human evaluation of CT-388 in a double blind, placebo controlled, randomized, SAD/MAD/MD, safety, tolerance, PK, and PD study when administered as a SC injection in otherwise healthy overweight and obese adult…
- Trial name
- NCT04838405
- Testing
- CT-388
- Where
- 2 sites in Australia, Mexico
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- Carmot Therapeutics, Inc.
Obese Adult Male
A Study of RTA 402 in Obese Adults
To investigate changes in body weight and body composition in obese adults after repeated oral administration of RTA 402 once daily for 16 weeks, using placebo as a control.
- Trial name
- NCT04018339
- Testing
- Bardoxolone methyl
- Where
- Japan
- Volunteers
- 22 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Overweight, Obesity
A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range
This study will look at how the investigational dose of semaglutide works in helping people with excess body weight, to lose weight.
- Trial name
- STEP12 (NCT06041217)
- Testing
- Semaglutide
- Where
- 21 sites in China, Taiwan
- Volunteers
- 242 people
- Sponsor
- Novo Nordisk A/S
Overweight , Obesity
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of IBIO-600 in Overweight or Obese Adults
The goal of this clinical trial is to learn which dose of study drug IBIO-600 has the right balance of safety, tolerability and impact on body composition in overweight and obese adult participants.
- Trial name
- NCT07487376
- Testing
- IBIO-600
- Where
- Australia
- Volunteers
- 32 people
- Sponsor
- iBio, Inc.
Obesity
A Study to Evaluate ALN-2232 in Participants With Obesity
The purpose of this study is to: evaluate the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of ALN-2232 in patients with obesity evaluate the safety, tolerability…
- Trial name
- NCT07463846
- Testing
- ALN-2232, Tirzepatide
- Where
- Canada
- Volunteers
- 156 people
- Sponsor
- Alnylam Pharmaceuticals
Obesity, Overweight
Taldefgrobep Alfa in Adults With Overweight and Obesity
This is a multicenter, randomized, double-blind, placebo-controlled, multiple dose study to evaluate the efficacy, safety, and tolerability of taldefgrobep alfa in adults with overweight and obesity, with an open-label extension.
- Trial name
- NCT07281495
- Testing
- Taldefgrobep Alfa
- Where
- 20 sites in United States
- Volunteers
- 150 people
- Sponsor
- Biohaven Therapeutics Ltd.
Overweight , Obesity
TRPTI Metabolic and GLP-1 Pharmacodynamic Study
The goal of this clinical trial is to assess whether TRPTI™ supplementation affects GLP-1 and related metabolic markers in generally healthy adults who are overweight or obese (BMI 25.0-34.9 kg/m², aged 30 years and older).
- Trial name
- NCT07850466
- Testing
- TRPTI
- Where
- Australia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- RDC Clinical Pty Ltd
Obesity, Type 2 Diabetes
MagDI Australia Study
The objective of the MagDI Australia Study is to evaluate the feasibility / performance, safety, and initial efficacy of the MagDI System in eligible participants who are indicated for a duodeno-ileal (small bowel) side-to-side…
- Trial name
- NCT06473831
- Testing
- Magnet System, DI Biofragmentable
- Where
- 4 sites in Australia
- Volunteers
- 25 people
- Sponsor
- GT Metabolic Solutions, Inc.
Obesity & Overweight
Evaluating the Efficacy and Safety of LUM-201 Plus Semaglutide Versus Semaglutide Plus Placebo in Older Obese Adults
This is a phase 2 randomized, double-blind, placebo-controlled, multi-center study evaluating the efficacy and safety of LUM-201 plus Semaglutide versus Semaglutide plus placebo in obese adults with body mass index between 30 and…
- Trial name
- NCT07754045
- Testing
- LUM-201, Semagludtide
- Volunteers
- 202 people
- Sponsor
- Lumos Pharma
Obesity, Overweight
A Multiple Dose Study Of PF-04620110 In Overweight And Obese, Otherwise Healthy Volunteers
PF-04620110 is a novel compound proposed for the treatment of Type 2 diabetes mellitus. The primary purpose of this trial is to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics, of multiple oral doses…
- Conditions
- Obesity, Overweight, Healthy
- Trial name
- NCT00959426
- Testing
- PF-04620110
- Where
- United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity, Overweight
A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Monthly Compared to Placebo in Chinese Adults With Overweight or Obesity
Overweight and obesity are long-term health conditions that can increase the possibility of serious health problems. These problems include heart disease, type 2 diabetes (a condition that causes high blood sugar), and other…
- Trial name
- NCT07874633
- Testing
- Berobenatide
- Where
- 2 sites in China
- Volunteers
- 432 people
- Sponsor
- Pfizer
Overweight and Obesity
Evaluate the Safety and Efficacy of HDM1002 Tablets in Chinese Overweight and Obese Adults
A Phase 3 Trial to Evaluate the Safety and Efficacy of HDM1002 Tablets in Overweight and Obese Adults
- Trial name
- NCT06885021
- Testing
- HDM1002 200mg, oral, once daily, 52 weeks, HDM1002 400mg, oral, once daily, 52 weeks
- Volunteers
- 780 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Obesity
A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease
The main purpose of this study is to investigate the efficacy and safety of oral orforglipron in participants with obesity disease with obesity-related health problems.
- Trial name
- ATTAIN-J (NCT05931380)
- Testing
- Orforglipron
- Where
- 16 sites in Japan
- Volunteers
- 238 people
- Sponsor
- Eli Lilly and Company
Chronic Weight Management
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Two Formulations of ASC36 Injection in Participants With Obesity or Overweight
This randomized, double-blind, placebo-controlled single ascending dose (SAD)/ multiple ascending dose (MAD) study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of Two Formulations of…
- Trial name
- NCT07893093
- Testing
- ASC36 Injection A, for subcutaneous use, ASC36 Injection B, for subcutaneous use
- Where
- 2 sites in United States
- Volunteers
- 144 people
- Sponsor
- Ascletis Pharma (China) Co., Limited
Obesity and Overweight
This Study Will Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MET097 in Adult Participants With Overweight or Obesity
The goal of this Phase 1/2 clinical trial is to assess the safety, tolerability, pharmacokinetics, and efficacy of once-weekly subcutaneous injections of MET097 in otherwise healthy adults with overweight or obesity.
- Trial name
- NCT06857617
- Testing
- (Part C) MET097
- Where
- 3 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Metsera, a wholly owned subsidiary of Pfizer
Overweight Subject, Healthy Subjects
A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin
The purpose of this study is to characterize the drug-drug intereaction of HDM1002 and metformin, empagliflozin, midazolam, valsartan, and warfarin in overweight/obese adult subjects.
- Trial name
- NCT07331389
- Testing
- Metformin, Empagliflozin, Midazolam
- Where
- China
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Obesity & Overweight
A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity
This study investigates the Topical-Lingual (T-L) delivery of semaglutide, a GLP-1 receptor agonist (GLP-1RA), via an oral liquid emulsion formulation as a Proof-of-Concept for the T-L delivery of metabolic hormones in general.
- Trial name
- NCT07728383
- Testing
- Semaglutide 6 mg liquid emulsion formulation, Wegovy® (semaglutide) Tablet
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Gila Therapeutics, Inc.
Overweight, Obesity
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes.
- Trial name
- ENLIGHTEN-2 (NCT07282600)
- Testing
- Eloralintide
- Where
- 143 sites in United States, China and 11 more
- Volunteers
- 1,035 people
- Sponsor
- Eli Lilly and Company
Diabetes, Obesity
A 12-WEEK TITRATE STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACODYNAMICS OF PF-06882961 IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND IN NON-DIABETIC ADULTS WITH OBESITY
This study will assess tolerability, safety, and pharmacodynamics (PD) of twice daily (BID) administration of PF- 06882961 in adult participants with Type 2 Diabetes Mellitus (T2DM) who are treated with metformin and in…
- Trial name
- NCT04617275
- Testing
- PF-06882961
- Where
- 38 sites in United States
- Volunteers
- 151 people
- Sponsor
- Pfizer